The effect of discontinuing beta-blockers after different treatment durations following acute myocardial infarction in optimally treated, stable patients without heart failure: a Danish, nationwide cohort study
- 30 June 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 9 (6) , 553-561
Abstract
Aims: We studied the effect of discontinuing beta-blockers following myocardial infarction in comparison to continuous beta-blocker use in optimally treated, stable patients without heart failure. Methods and results: Using nationwide registers, we identified first-time myocardial infarction patients treated with beta-blockers following percutaneous coronary intervention or coronary angiography. The analysis was based on landmarks selected as 1, 2, 3, 4, and 5 years after the first redeemed beta-blocker prescription date. The outcomes included all-cause death, cardiovascular death, recurrent myocardial infarction, and a composite outcome of cardiovascular events and procedures. We used logistic regression and reported standardized absolute 5-year risks and risk differences at each landmark year. Among 21 220 first-time myocardial infarction patients, beta-blocker discontinuation was not associated with an increased risk of all-cause death, cardiovascular death, or recurrent myocardial infarction compared with patients continuing beta-blockers (landmark year 5; absolute risk difference [95% confidence interval]), correspondingly; −4.19% [−8.95%; 0.57%], −1.18% [−4.11%; 1.75%], and −0.37% [−4.56%; 3.82%]). Further, beta-blocker discontinuation within 2 years after myocardial infarction was associated with an increased risk of the composite outcome (landmark year 2; absolute risk [95% confidence interval] 19.87% [17.29%; 22.46%]) compared with continued beta-blocker use (landmark year 2; absolute risk [95% confidence interval] 17.10% [16.34%; 17.87%]), which yielded an absolute risk difference [95% confidence interval] at −2.8% [−5.4%; −0.1%], however, there was no risk difference associated with discontinuation hereafter. Conclusion: Discontinuation of beta-blockers 1 year or later after a myocardial infarction without heart failure was not associated with increased serious adverse events.Keywords
Funding Information
- Bayer
- Novo Nordisk
- Medtronic
This publication has 33 references indexed in Scilit:
- Clinical Outcomes with β-Blockers for Myocardial Infarction: A Meta-analysis of Randomized TrialsThe American Journal of Medicine, 2014
- β-BlockersAnnals of Pharmacotherapy, 2014
- 2013 ACCF/AHA Guideline for the Management of ST‐Elevation Myocardial Infarction: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesCatheterization and Cardiovascular Interventions, 2013
- The Danish Register of Causes of DeathScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Optimal Medical Therapy for Non–ST-Segment–Elevation Acute Coronary SyndromesCirculation: Cardiovascular Quality and Outcomes, 2010
- Modeling cumulative incidence function for competing risks dataExpert Review of Clinical Pharmacology, 2008
- Early intravenous then oral metoprolol in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trialThe Lancet, 2005
- Expert consensus document on ?-adrenergic receptor blockersThe Task Force on Beta-Blockers of the European Society of CardiologyEuropean Heart Journal, 2004
- ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction—Executive SummaryJACC, 2004